Certain biomarkers in CSF have shown promising diagnostic value for PCNSL, particularly the myeloid differentiation factor 88 (MYD88) L265P mutation in cell-free DNA (MYD88-cfDNA) and interleukin-10 (IL10) [12]. Here, MYD88 is linked to primary central nervous system lymphoma.